Przegląd Menopauzalny

Abstract

4/2002 vol. 1

Clinical efficacy and tolerance of oral low-dose continuous estrogen-progestin therapy (Activelle)

(Prz Menopauz 2002; 4: 35–38)
Online publish date: 2004/03/03
View full text
New therapeutical option for hrt – oral low-dose continuous estrogen-progestin therapy with the use of 1 mg estradiol and 0.5 mg norethisterone acetate was evaluated in the article. We find Activelle (Novo Nordisk) effective in the treatment of menopausal symptoms. This drug is well tolerated by postmenopausal women. The frequency of side effects is low. The most common is spotting/bleeding: 22.6% patients in the first month of hrt, 6.9% treated women after 6 months.
Share
without publication fees